Floatz logo

COLCHICINUM

Dependence

Population Health Research InstituteSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Dependence cohort.

Asset / SponsorPhaseRating
Naltrexone
Inventage Lab., Inc.
Phase 4BBB
Acamprosate
Hanyang University Seoul Hospital
Phase 4BBB
Seroquel®
University of Texas Southwestern Medical Center
Phase 4BBB
Cipralex
University of Texas Southwestern Medical Center
Phase 4BBB
Topamax
Stanford University
Phase 4BB

View all 27 →

Same molecule, other indications

COLCHICINUM is also rated in:

cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
fibrotic liver diseaseDormant
BB
Indicative ·
69 / 100
View asset →
hepatitis C virus infectionDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →